Literature DB >> 23706103

High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia.

Juan Long1, Shan Liu, Kang Li, Xiaoyan Zhou, Penghui Zhang, Lin Zou.   

Abstract

The CD34+/CD38- immunophenotype is used to identify candidate hematopoietic stem cells (HSCs) and leukemia-initiating cells (LICs). However, the clinical significance of the CD34+/CD38-proportion in childhood acute lymphoblastic leukemia (ALL) is not well established. Here, we found that a high proportion of CD34+/CD38- cells from 112 patients with childhood ALL was negatively correlated with the outcome. Also the percentage of CD34+/CD38- cells was associated with clinical and biological features of patients with ALL. Further, a high proportion of CD34+/CD38- cells in childhood ALL was positively correlated with advanced risk subgroups, which could predict risk stratification by receiver operating characteristic (ROC) curve analysis. In addition, a larger tumor burden and lower survival rate were observed in mice injected with CD34+/CD38- cells, but not in mice injected with other fractions. Our data reveal that a high proportion of CD34+/CD38- cells is positively associated with a poor prognosis of childhood ALL, to further guide therapy of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706103     DOI: 10.3109/10428194.2013.807924

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Immuno-phenotypes and prognosis of acute leukemia in elderly patients.

Authors:  Fanmei Ge; Baoli Li; Xuemei Gao; Yu Ren; Hui Liu; Baoxiong Su; Yuhong Liu; Huiqin Cao
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 2.  CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia.

Authors:  Zhiwu Jiang; Di Wu; Shouheng Lin; Peng Li
Journal:  Biomark Res       Date:  2016-12-16

3.  Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR.

Authors:  Zhe-Xin Shi; Hong-Yu Li; Xiang-Dong Yang; Hong Gao; De-Guan Li; Wen-Hua Yang; Fang Yao; Li-Xiang Yan
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 4.  Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.

Authors:  Tiziana Vaisitti; Francesca Arruga; Giulia Guerra; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

5.  Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis.

Authors:  Nadia El-Menshawy; Sherin M Abd-Aziz; Enas M Elkhamisy; Mohammed A Ebrahim
Journal:  Blood Res       Date:  2018-06-25

6.  Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.

Authors:  Chen Zhu; Zhili Song; Anlai Wang; Srimathi Srinivasan; Guang Yang; Rita Greco; Joachim Theilhaber; Elvis Shehu; Lan Wu; Zhi-Yong Yang; Wilfried Passe-Coutrin; Alain Fournier; Yu-Tzu Tai; Kenneth C Anderson; Dmitri Wiederschain; Keith Bahjat; Francisco J Adrián; Marielle Chiron
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.